Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 2, 2010, Pages 209-214

  Ramanathan, Srinivasan ^a   Abel, Samantha ^b   Tweedy, Sarah ^c   West, Steve ^d   Hui, James ^d   Kearney, Brian P ^a  

^a GILEAD SCIENCES   (United States)

^b Valley Writing Solutions Ltd   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d GILEAD SCIENCES INC   (United States)

Author keywords

CCR5; Elvitegravir; Integrase; Interaction; Maraviroc; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A; ELVITEGRAVIR; GLYCOPROTEIN P; MARAVIROC; RITONAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEATH; DRUG INHIBITION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROLOGIC DISEASE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOHEXANES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; QUINOLONES; RITONAVIR; TRIAZOLES; YOUNG ADULT;

EID: 75649141590     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ba4536     Document Type: Article

References (25)

1. Ramanathan S, Wright M, West S, et al. Pharmacokinetics, metabolism, and excretion of ritonavir-boosted GS-9137 (Elvitegravir). Presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary. Abstract 30.
2. Mathias AA, West S, Hui J, et al. Effect of increasing ritonavir doses on hepatic CYP3A activity and GS-9137 (elvitegravir) oral exposure. Presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary. Abstract 53.
3. Ramanathan S, West S, Hui J, et al. Clinical pharmacokinetics of once-daily elvitegravir boosted by ritonavir versus atazanavir. Presented at: Ninth International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA. Abstract O18.
4. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5.
5. Zolopa A, Lampiris H, Blick G, et al. The HIV integrase inhibitor elvitegravir (EVG/r) has potent and durable antiretroviral activity in treatment-experienced patients with active optimized background therapy (OBT) [H-714]. Presented at: Forty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL.
6. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients [143LB]. Presented at: Fourteenth Conference on Retrovirus and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
7. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1a, and MIP-1b as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
8. Arenzana-Seisdedos, F, Virelizier, JL, Rousset D, et al. HIV blocked by chemokine antagonist. Nature. 1996;383:400.
9. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359: 1429-1441.
10. Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmcol. 2008;66:498-507.
11. Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos. 2005;33:587-595.
12. Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther. 2009;14:607-618.
13. Ramanathan S, Kakuda TN, Mack, R, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther. 2008;13:1011-1017.
14. Abel S, Russell D, Whitlock LA, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloe-stradiol/ levonorgestrel in healthy volunteers. Br J Clin Pharmacol. 2008; 65(Suppl 1):19-26.
15. Mathias AA, Hinkle J, Shen G, et al. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr. 2008;49:156-162.
16. Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following co-administration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr. 2007;45:274-279.
17. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetics of co-administered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, and abacavir. J Acquir Immune Defic Syndr. 2007;46:160-166.
18. Mathias AA, Hinkle J, Shen G, et al. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr. 2008;49:156-162.
19. Ramanathan S, Mathias AA, Shen G, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r [WEBEP014]. Presented at: Fourth International AIDS Society Conference on Pathogenesis, Treatment, and Prevention; 2007; Sydney, Australia.
20. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents. Presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary. Abstract 69.
21. Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl 1): 38-46.
22. Muirhead G, Abel S, Russell D, et al. An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Presented at: 7th International congress on drug therapy in HIV infection [P283]; November 14-18, 2004; Glasgow, United Kingdom.
23. Abel S, Ridgway C, Hamlin J, et al. An open, randomized, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects. Presented at: Eighth International Workshop on Pharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary. Abstract 55.
24. Mathias AA, West S, Hui J, et al. Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure. Clin Pharmacol Ther. 2008;85:64-70.
25. Muirhead G, Ridgway C, Leahy D. A study to investigate the combined coadministration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857 [P284]. Presented at: Seventh International congress on drug therapy in HIV infection; November 14-18, 2004; Glasgow, United Kingdom.